Bvf Inc/il 13F annual report

Bvf Inc/il is an investment fund managing more than $3.57 trillion ran by Mark Lampert. There are currently 59 companies in Mr. Lampert’s portfolio. The largest investments include Moonlake Immunotherapeutics and Revolution Medicines Inc, together worth $1.19 trillion.

Limited to 30 biggest holdings

$3.57 trillion Assets Under Management (AUM)

As of 7th August 2024, Bvf Inc/il’s top holding is 21,751,284 shares of Moonlake Immunotherapeutics currently worth over $956 billion and making up 26.8% of the portfolio value. In addition, the fund holds 5,981,212 shares of Revolution Medicines Inc worth $232 billion, whose value grew 44.7% in the past six months. The third-largest holding is Kymera Therapeutics worth $154 billion and the next is Ionis Pharmaceuticals Inc worth $152 billion, with 3,186,376 shares owned.

Currently, Bvf Inc/il's portfolio is worth at least $3.57 trillion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Bvf Inc/il

The Bvf Inc/il office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Mark Lampert serves as the President at Bvf Inc/il.

Recent trades

In the most recent 13F filing, Bvf Inc/il revealed that it had opened a new position in Axsome Therapeutics Inc and bought 955,000 shares worth $76.9 billion. This means they effectively own approximately 0.1% of the company. Axsome Therapeutics Inc makes up 4.6% of the fund's Health Care sector allocation and has grown its share price by 18.4% in the past year.

The investment fund also strengthened its position in Ionis Pharmaceuticals Inc by buying 757,763 additional shares. This makes their stake in Ionis Pharmaceuticals Inc total 3,186,376 shares worth $152 billion. Ionis Pharmaceuticals Inc soared 17.6% in the past year.

On the other hand, there are companies that Bvf Inc/il is getting rid of from its portfolio. Bvf Inc/il closed its position in Syndax Pharmaceuticals Inc on 14th August 2024. It sold the previously owned 1,875,000 shares for $44.6 billion. Mark Lampert also disclosed a decreased stake in Protagonist Therapeutics Inc by 0.1%. This leaves the value of the investment at $115 billion and 3,319,290 shares.

One of the largest hedge funds

The two most similar investment funds to Bvf Inc/il are Wilbanks Smith & Thomas Asset Management and Equity Investment Corp. They manage $3.57 trillion and $3.56 trillion respectively.


Mark Lampert investment strategy

Bvf Inc/il’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 47.0% of the total portfolio value. The fund focuses on investments in the United States as 42.4% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are small-cap stocks. Stocks with a size of more than $100 million in market cap make up 17% of the total holdings value. On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $714 million.

The complete list of Bvf Inc/il trades based on 13F SEC filings

These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security Shares Owned Value Allocation
Moonlake Immunotherapeutics
No change
21,751,284
$956,403,957,000 26.81%
Revolution Medicines Inc
No change
5,981,212
$232,130,838,000 6.51%
Kymera Therapeutics, Inc.
No change
5,161,801
$154,079,760,000 4.32%
Ionis Pharmaceuticals Inc
31.20%
3,186,376
$151,862,680,000 4.26%
Mirum Pharmaceuticals Inc
No change
4,370,024
$149,411,121,000 4.19%
Gh Research Plc
No change
10,400,158
$121,265,842,000 3.40%
Protagonist Therapeutics Inc
11.63%
3,319,290
$115,013,399,000 3.22%
Cullinan Therapeutics Inc
79.89%
5,750,683
$100,291,912,000 2.81%
Olema Pharmaceuticals, Inc.
No change
9,135,893
$98,850,362,000 2.77%
Structure Therapeutics Inc
206.00%
2,487,762
$97,694,414,000 2.74%
Xoma Corp Del
No change
3,633,743
$86,083,372,000 2.41%
Kura Oncology Inc
14.71%
4,082,037
$84,049,142,000 2.36%
4d Molecular Therapeutics In
No change
3,922,413
$82,331,449,000 2.31%
Axsome Therapeutics Inc
Opened
955,000
$76,877,500,000 2.16%
Cg Oncology Inc
28.32%
2,417,885
$76,332,629,000 2.14%
Merus N.V
9.11%
1,279,049
$75,681,329,000 2.12%
AC Immune SA
29.26%
18,834,936
$75,151,395,000 2.11%
Tyra Biosciences Inc
No change
4,661,194
$74,532,492,000 2.09%
89bio Inc
87.00%
7,568,479
$60,623,517,000 1.70%
Celcuity Inc
Opened
3,466,000
$56,773,080,000 1.59%
Third Harmonic Bio Inc
No change
4,365,933
$56,757,129,000 1.59%
Agios Pharmaceuticals Inc
Opened
1,190,107
$51,317,414,000 1.44%
Zymeworks Inc
No change
5,870,000
$49,953,700,000 1.40%
Essa Pharma Inc
No change
8,748,629
$46,017,788,000 1.29%
Syndax Pharmaceuticals Inc
Closed
1,875,000
$44,625,000,000
IDEAYA Biosciences, Inc.
No change
1,162,306
$40,808,564,000 1.14%
Galapagos NV
15.79%
1,569,422
$38,890,277,000 1.09%
Annexon Inc
No change
7,000,000
$34,300,000,000 0.96%
Repare Therapeutics Inc.
No change
10,333,600
$34,100,880,000 0.96%
Foghorn Therapeutics Inc.
Opened
5,302,000
$30,486,500,000 0.85%
Calliditas Therapeutics AB
No change
750,000
$29,242,500,000 0.82%
Newamsterdam Pharma Company
No change
1,521,948
$29,236,621,000 0.82%
Roivant Sciences Ltd
No change
2,742,409
$28,987,263,000 0.81%
Engene Holdings Inc
No change
2,251,037
$21,227,279,000 0.60%
Janux Therapeutics Inc
84.88%
441,528
$18,495,608,000 0.52%
Tscan Therapeutics Inc
No change
2,989,474
$17,488,423,000 0.49%
Eledon Pharmaceuticals, Inc.
45.45%
6,293,282
$16,614,264,000 0.47%
Allakos Inc
No change
16,552,417
$16,552,417,000 0.46%
Immunic, Inc.
No change
8,902,972
$9,882,299,000 0.28%
Ikena Oncology Inc
No change
4,769,164
$7,869,121,000 0.22%
Vigil Neuroscience Inc
No change
1,813,633
$7,254,532,000 0.20%
Vistagen Therapeutics Inc.
No change
2,000,000
$6,960,000,000 0.20%
CytomX Therapeutics Inc
20.73%
5,228,461
$6,378,722,000 0.18%
Cidara Therapeutics Inc
Closed
6,861,127
$6,312,237,000
Elevation Oncology Inc
No change
2,312,200
$6,242,940,000 0.18%
Delcath Sys Inc
Closed
1,202,067
$5,733,860,000
Verastem Inc
No change
1,685,219
$5,021,953,000 0.14%
Cidara Therapeutics Inc
Opened
343,055
$4,096,077,000 0.11%
Lexicon Pharmaceuticals Inc
Closed
1,686,924
$4,048,618,000
An2 Therapeutics Inc
Closed
1,239,470
$4,028,278,000
Kronos Bio, Inc.
Closed
2,905,043
$3,776,556,000
Pieris Pharmaceuticals Inc
Closed
20,609,863
$3,775,727,000
Verve Therapeutics Inc
No change
650,000
$3,172,000,000 0.09%
Molecular Partners Ag
No change
443,221
$3,169,030,000 0.09%
Ovid Therapeutics Inc
No change
3,853,818
$2,964,357,000 0.08%
Sab Biotherapeutics Inc
No change
917,826
$2,845,261,000 0.08%
GlycoMimetics Inc
No change
9,544,262
$2,687,664,000 0.08%
Pieris Pharmaceuticals Inc
Opened
257,626
$2,545,345,000 0.07%
Inventiva Sa
No change
686,040
$2,023,818,000 0.06%
Viracta Therapeutics Inc
No change
3,614,662
$1,965,292,000 0.06%
Forte Biosciences, Inc.
No change
2,982,105
$1,601,390,000 0.04%
Nls Pharmaceutics Ltd
No change
5,747,126
$1,246,552,000 0.03%
Unicycive Therapeutics Inc
39.09%
2,200,000
$1,102,420,000 0.03%
Rezolute Inc
No change
190,815
$820,505,000 0.02%
Corvus Pharmaceuticals Inc
Closed
361,406
$643,303,000
Molecular Templates Inc
No change
522,238
$600,574,000 0.02%
ASLAN Pharmaceuticals Ltd
No change
1,049,999
$315,000,000 0.01%
No transactions found
Showing first 500 out of 67 holdings